Effect of WEB 2086-BS, an antagonist of platelet-activating factor receptors, on retinal vascularity in diabetic rats

European Journal of Pharmacology

Volumn 360, Issue 1, 1998, Pages 37-42

  De La Cruz, José Pedro ^a   Moreno, Antonio ^a   Ruiz Ruiz, María Isabel ^a   García Campos, José ^a   Sánchez De La Cuesta, Felipe ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Diabetic retinopathy; PAF (platelet activating factor); Platelet; Thromboxane lipid peroxidation

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; APAFANT; COLLAGEN; HORSERADISH PEROXIDASE; INSULIN; ISOPHANE INSULIN; LIPID PEROXIDE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ICOSANOID METABOLISM; LIPID PEROXIDATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; RETINA BLOOD VESSEL; STREPTOZOCIN DIABETES; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION;

ANALYSIS OF VARIANCE; ANIMALS; AZEPINES; BLOOD GLUCOSE; BLOOD PLATELETS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; LIPID PEROXIDATION; MALE; NEOVASCULARIZATION, PATHOLOGIC; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; RATS; RATS, WISTAR; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; RETINA; THROMBOXANE B2; TRIAZOLES;

EID: 18244412375     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00664-5     Document Type: Article

References (25)

1. Brambilla A., Ghiorzi A., Giachetti A. WEB 2086, a potent PAF receptor antagonist exerts protective effect against PAF-induced gastric damage. Pharmacol. Res. Commun. 19:1987;147-151.
2. Cardinal D.C., Flower R.F. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J. Pharmacol. Methods. 3:1980;135-158.
3. Carter A.J., Hanley S.P. The effect of platelet number and haematocrit on whole blood thromboxane synthesis. Thromb. Haemost. 53:1985;225-227.
4. Casals-Stenzel J., Muacevic G., Weber K.H. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. J. Pharmacol. Exp. Ther. 241:1987;974-981.
5. Chung K.F., Aizawa H., Leikauf G.D., Ueki I.F., Evans T.W., Nadel J.A. Airway hyperresponsiveness induced by platelet-activating factor: role of thromboxane generation. J. Pharmacol. Exp. Ther. 236:1986;580-584.
6. de la Cruz J.P., Moreno A., Garcia Campos J.M., Sánchez de la Cuesta F. Effect of antiplatelet drug therapy on the retinal vascular pattern in experimental diabetes mellitus. Can. J. Ophthalmol. 25:1990;329-332.
7. de la Cruz J.P., Moreno A., Mérida F., García Campos J.M., Sánchez de la Cuesta F. The pyrimido-pyrimidine derivatives, dipyridamole and RA-642, reduce opacification of crystalline lens in diabetic rats. Pharmacol. Toxicol. 75:1994;250-254.
8. De la Cruz J.P., Moreno A., Mérida F., García Campos J.M., Sánchez de la Cuesta F. The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus. Thromb. Res. 81:1996;27-337.
9. de la Cruz J.P., Moreno A., Muñoz M., García Campos J.M., Sánchez de la Cuesta F. Effect of aspirin plus dipyridamole on the retinal vascular pattern in experimental diabetes mellitus. J. Pharmacol. Exp. Ther. 280:1997;454-459.
10. de la Cruz J.P., Moreno A., Sintas A., García Campos J.M., Sánchez de la Cuesta F. Platelet hyperaggregation in diabetic patients with different types of retinopathy is partially influenced by erythrocytes in whole blood. Diabetes Res. 32:1997;51-68.
11. de la Cruz J.P., Moreno A., Ruiz-Ruiz M.I., García Campos J.M., Sánchez de la Cuesta F. Effects of Camonagrel, a selective thromboxane-synthase inhibitor, on retinal vascularization in experimental dianetes. Eur. J. Pharmacol. 350:1998;81-85.
12. Evans T.W., Chung K.F., Rogers D.F., Barnes P.J. Effect of platelet-activating factor on airway vascular permeability: possible mechanisms. J. Appl. Physiol. 63:1987;479-484.
13. Gonzalez, D., Wintz, A., 1987. Digital Image Processing. Addison-Wesley Publishing, London.
14. Hendra T., Betteridge D.J. Platelet function, platelet prostanoids and vascular prostacyclin in diabetes mellitus. Prostaglandins Leukotrienes Essent. Fatty Acids. 35:1989;197-212.
15. Ishii H., Umeda F., Nawata H. Platelet function in diabetes mellitus. Diabetes Metab. Res. 8:1992;53-66.
16. Kato M., Tokuyama K., Morikawa A., Kuroume T., Barnes P.J. Platelet-activating factor-induced enhancement of superoxide anion generation in guinea-pigs. Eur. J. Pharmacol. 232:1993;7-12.
17. Lellouch-Tubiana A., Lefort J., Pirotzky E., Vargaftig B.B., Pfister A. Ultrastructural evidence for extravascular platelet recruitment in the lung upon intravenous injection of platelet-activating factor (PAF-acether) to guinea-pigs. Br. J. Exp. Pathol. 66:1985;345-355.
18. Mesulam, M., 1982. Tracing Neural Connections with Horseradish Peroxidase. Wiley-Interscience, Boston, MA.
19. Moreno A., de la Cruz J.P., García Campos J., Sánchez de la Cuesta F. Prostacyclin-thromboxane balance and retinal vascular pattern in rats with experimentally induced diabetes. Can. J. Ophthalmol. 30:1995;117-123.
20. Moreno A., de la Cruz J.P., García Campos J.M., Sánchez de la Cuesta F. Effects of ditazol on the vascular retinal pattern in experimental diabetes in rats. Haemostasis. 25:1995;166-171.
21. O'Donnell S.R., Barnett C.J.K. PAF induced aggregation of rabbit platelets. Comparison of antagonist drugs. Clin. Exp. Pharmacol. Physiol. 1:1981;11-15.
22. O'Rourke F.A., Halenda S.P., Zavoico G.B., Feinstein M.B. Inositol 1,4,5-triphosphate releases Ca2+ from a Ca2+-transporting membrane vesicle fraction derived from human platelets. J. Biol. Chem. 260:1985;956-962.
23. Shukla S.D., Paul A., Klachko D.M. Hypersensitivity of diabetic human platelets to platelet activating factor. Thromb. Res. 66:1992;239-246.
24. Stevenson J.S., Tallent M., Blinder L., Abraham W.M. Modification of antigen-induced late response with an antagonist of platelet activating factor (WEB 2086-BS). Fed. Proc. 46:1987;1491.
25. Warso M.A., Lands W. Lipid peroxidation in relation to prostacyclin and thromboxane physiology and pathophysiology. Br. Med. Bull. 39:1983;277-280.